MNG215
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- ALLOGRAFT_REJECTION+0.472
- INTERFERON_GAMMA_RESPONSE+0.417
- TNFA_SIGNALING_VIA_NFKB+0.401
- IL6_JAK_STAT3_SIGNALING+0.388
- APICAL_SURFACE+0.351
- INFLAMMATORY_RESPONSE+0.350
- COMPLEMENT+0.347
- INTERFERON_ALPHA_RESPONSE+0.342
- PROTEIN_SECRETION+0.333
- KRAS_SIGNALING_UP+0.315
Top 10 suppressed
- OXIDATIVE_PHOSPHORYLATION-0.315
- NOTCH_SIGNALING-0.244
- PEROXISOME-0.234
- MYC_TARGETS_V2-0.228
- CHOLESTEROL_HOMEOSTASIS-0.200
- FATTY_ACID_METABOLISM-0.166
- DNA_REPAIR-0.104
- ESTROGEN_RESPONSE_LATE-0.093
- GLYCOLYSIS-0.083
- BILE_ACID_METABOLISM-0.063
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-FD-A3B8-01A-31R-A20F-07 | — | — | 0.870 |
| 2 | c7a22797-676e-4f10-a51d-e3ee91a29a21 | — | — | 0.853 |
| 3 | TCGA-DK-A2I4-01A-11R-A21D-07 | — | — | 0.849 |
| 4 | SRR8518406 | — | D | 0.848 |
| 5 | SJEPD030232_D1.RNA-Seq | EPN | Posterior Fossa EPN | 0.847 |
| 6 | SRR1516052 | — | — | 0.843 |
| 7 | TCGA-BH-A1F0-01A-11R-A137-07 | — | D | 0.837 |
| 8 | c55bb20b-c929-42e2-be7f-8b1da7bee953 | — | — | 0.831 |
| 9 | TCGA-GV-A3QG-01A-11R-A220-07 | — | — | 0.829 |
| 10 | SRR23303739 | — | — | 0.825 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 35 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| ALLOGRAFT_REJECTION | 0.472 | Idelalisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.417 | Idelalisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.401 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.388 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.351 | Temsirolimus | — uncovered |
| INFLAMMATORY_RESPONSE | 0.350 | Idelalisib | — uncovered |
| COMPLEMENT | 0.347 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.342 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.333 | Remibrutinib | — uncovered |
| KRAS_SIGNALING_UP | 0.315 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.304 | Inavolisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.297 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.284 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.281 | Idelalisib | — uncovered |
| APOPTOSIS | 0.244 | Idelalisib | — uncovered |
| TGF_BETA_SIGNALING | 0.238 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.233 | Remibrutinib | — uncovered |
| G2M_CHECKPOINT | 0.212 | Inavolisib | — uncovered |
| HYPOXIA | 0.185 | Idelalisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.174 | Inavolisib | — uncovered |